Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases

verfasst von: Tadashi Terada

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma (BCC) has rarely been investigated. The author immunohistochemically examined the expression of these molecules in 66 consecutive cases of BCC. In non-tumorous skin, NCAM chromogranin A, synaptophysin, c-KIT and PDGFRA expression was seen in the basal cell of the epidermis. NCAM, c-KIT and PDGFRA expression was also seen in the sweat glands and outer cells of hair follicles, but chromogranin and synaptophysin expression was not identified in these structures. In BCC, NCAM expression was seen in 95 % (63/66 cases). Its expression was membranous. Chromogranin A expression was recognized in 27 % (18/66 cases). Its expression was cytoplasmic. Synaptophysin expression was seen in 18 % (12/66 cases). Its expression was membranous and cytoplasmic. c-KIT expression was noted in 93 % (61/66 cases). Its expression was membranous and focally cytoplasmic. PDGFRA expression was seen in 65 % (43/66 cases). Its expression was membranous and cytoplasmic. The expression of these molecules in normal non-tumorous skin is a new finding. The expression of c-KIT and PDGFRA in BCC is also a new finding. In conclusion, the author described the normal (non-neoplastic) distribution of NCAM, chromogranin A, synaptophysin, c-KIT and PDGFRA. In addition, the author showed that, in cutaneous BCC, the expression of NCAM and c-KIT was high (95 and 93 % respectively), PDGFRA was intermediate (65 %), and chromogranin A and synaptophysin was relatively low (27 and 18 %, respectively).
Literatur
1.
Zurück zum Zitat Kossard S, Epstein Jr EH, Cerio R, Yu LL, Weedon D. Basal cell carcinoma. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World health organization classification of tumours. Pathology and genetics of skin tumours. Lyon: IARC Press; 2006. p. 13–19. Kossard S, Epstein Jr EH, Cerio R, Yu LL, Weedon D. Basal cell carcinoma. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World health organization classification of tumours. Pathology and genetics of skin tumours. Lyon: IARC Press; 2006. p. 13–19.
2.
Zurück zum Zitat Dardi LE, Memoli VA, Gould VE. Neuroendocrine differentiation in basal cell carcinoma. J Cutan Pathol. 1981;8:335–41.PubMedCrossRef Dardi LE, Memoli VA, Gould VE. Neuroendocrine differentiation in basal cell carcinoma. J Cutan Pathol. 1981;8:335–41.PubMedCrossRef
3.
Zurück zum Zitat Visser R, Bosman FT. Neuroendocrine differentiation in basal cell carcinoma: a retrospective immunohistochemical and ultrastructural study. J Cutan Pathol. 1985;12:117–24.PubMedCrossRef Visser R, Bosman FT. Neuroendocrine differentiation in basal cell carcinoma: a retrospective immunohistochemical and ultrastructural study. J Cutan Pathol. 1985;12:117–24.PubMedCrossRef
4.
Zurück zum Zitat George E, Swanson PE, Wick MR. Neuroendocrine differentiation in basal cell carcinoma: an immunohistochemical study. Am J Dermatopathol. 1989;11:131–5.PubMedCrossRef George E, Swanson PE, Wick MR. Neuroendocrine differentiation in basal cell carcinoma: an immunohistochemical study. Am J Dermatopathol. 1989;11:131–5.PubMedCrossRef
5.
Zurück zum Zitat Ishida M, Kurashima R, Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep. 2009;22:733–7.PubMed Ishida M, Kurashima R, Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep. 2009;22:733–7.PubMed
6.
Zurück zum Zitat Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissue, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRef Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissue, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRef
7.
Zurück zum Zitat Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.PubMedCrossRef Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.PubMedCrossRef
8.
Zurück zum Zitat Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;206:271–5.PubMedCrossRef Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;206:271–5.PubMedCrossRef
9.
Zurück zum Zitat Beljaards RC, Kirtschig G, Boorsma DM. Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg. 2008;34:1577–79. Beljaards RC, Kirtschig G, Boorsma DM. Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg. 2008;34:1577–79.
10.
Zurück zum Zitat Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed and paraffin-embedded tissues. Virchows Arch. 1994;424:135–41.PubMedCrossRef Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed and paraffin-embedded tissues. Virchows Arch. 1994;424:135–41.PubMedCrossRef
11.
Zurück zum Zitat Blumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK, Sjolund K, Nilsson B. Gastrointestinal strumal tumor regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer. 2007;14:853–63.CrossRef Blumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK, Sjolund K, Nilsson B. Gastrointestinal strumal tumor regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer. 2007;14:853–63.CrossRef
12.
Zurück zum Zitat Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. A role of PGDFRα in basal cell carcinoma proliferation. Proc Natl Acad Sci USA. 2001;98:9255–9.PubMedCrossRef Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. A role of PGDFRα in basal cell carcinoma proliferation. Proc Natl Acad Sci USA. 2001;98:9255–9.PubMedCrossRef
Metadaten
Titel
Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases
verfasst von
Tadashi Terada
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0444-0

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.